Cyclacel Pharmaceuticals (CYCC) announces Q3 results and says it expects its $35M in cash to be enough to last through the completion of SEAMLESS (that's sapacitabine in AML), which is near the 50% enrollment mark.
The company also reminds investors that primary outcomes from sapacitabine in MDS (Phase 2) will be reported at ASH.
R&D for the quarter comes in at $4.6M, up sharply thanks (in part) to manufacturing costs for SEAMLESS.
CYCC also plans (in the next 12 months) to: "Announce registration-directed, clinical development plan for sapacitabine in MDS after treatment failure of hypomethylating agents [and] report updated data from the Phase 1 study of sapacitabine and seliciclib in patients with advanced solid tumors, including BRCA carriers." (PR)